Botanix Pharmaceuticals Ltd
BOT
Company Profile
Business description
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.
Contact
41 - 47 Colin Street
Suite 3
West PerthWA6005
AUST: +61 865552945
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
1
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,934.30 | 45.10 | -0.50% |
| CAC 40 | 7,834.58 | 16.30 | 0.21% |
| DAX 40 | 24,217.50 | 78.43 | -0.32% |
| Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
| FTSE 100 | 9,120.31 | 18.06 | -0.20% |
| HKSE | 25,388.35 | 278.83 | -1.09% |
| NASDAQ | 21,108.32 | 50.36 | 0.24% |
| Nikkei 225 | 41,456.23 | 370.11 | -0.88% |
| NZX 50 Index | 12,853.46 | 48.33 | 0.38% |
| S&P 500 | 6,388.64 | 25.29 | 0.40% |
| S&P/ASX 200 | 8,666.90 | 42.50 | -0.49% |
| SSE Composite Index | 3,593.66 | 12.07 | -0.33% |